The U.S. Food and Drug Administration simply authorized bremelanotide as an innovative new pharmaceutical treatment plan for pre-menopausal ladies with low libido. Marketed beneath the manufacturer Vyleesi, the medication that is injectable utilized to deal with just just what happens to be called hypoactive sexual interest disorder (HSDD). It’s the 2nd libido-enhancing medicine on industry for females. (the very first, Addyi, ended up being authorized in 2015 and it is a once-a-day tablet made to increase libido. )
Statistics vary, but significantly more than a 3rd of females report having low or libido that is limited 10 % have actually HSDD. Many — but, it is important to see, not totally all — are searching for assist to increase their sexual interest.
We talked with Stacy Tessler Lindau, MD, MA, a teacher within the Department of Obstetrics and Gynecology and a specialist in intimate function whom operates the University of Chicago Medicine’s Program in Integrative Sexual Medicine and WomanLab.org, to find out more about exactly what this latest pharmaceutical option means for females. Continue reading